ClinActiv Holdings Inc. and its subsidiary have completed the acquisition of all issued and outstanding common shares of Crescita Therapeutics Inc. [1]
This transaction marks the finalization of a previously announced plan of arrangement. By absorbing Crescita, ClinActiv consolidates its position in the pharmaceutical sector and gains full control over the assets of the Quebec-based entity [1], [2].
Crescita Therapeutics, which maintains its head office at 2805 Place Louis-R-Renaud in Laval, Québec [2], had previously coordinated with shareholders to facilitate this transition. The process included a special meeting for shareholders that took place on May 14, 2026, at 9 a.m. Toronto time [3].
The closing of the arrangement ensures that the ownership of Crescita is fully transferred to the purchaser's subsidiary [1]. This move eliminates the previous independent listing of Crescita on the TSX and OTC U.S. markets [1].
Company representatives said the closing follows the satisfaction of all necessary conditions outlined in the original plan of arrangement [1]. The transition allows for the integration of Crescita's operations into the broader ClinActiv corporate structure [1], [2].
“ClinActiv Holdings Inc. and its subsidiary have completed the acquisition of all issued and outstanding common shares of Crescita Therapeutics Inc.”
The acquisition of Crescita Therapeutics by ClinActiv Holdings represents a strategic consolidation of pharmaceutical assets. By moving from a public listing to a subsidiary model, the combined entity can streamline research and development efforts without the immediate pressure of public quarterly reporting for the Crescita arm.
